- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dan Leonard Addresses Barriers to Patient Involvement in Research
The industry has seen a lot of progress when it comes to involving patients more and earlier in the research progress, Dan Leonard, president of the National Pharmaceutical Council, said at the Pharmaceutical Quality Alliance's 10th Annual Meeting.
The industry has seen a lot of progress when it comes to involving patients more and earlier in the research progress, Dan Leonard, president of the National Pharmaceutical Council, said at the Pharmaceutical Quality Alliance's 10th Annual Meeting.
For example, patients are being used earlier when it comes to usability and developing criteria for improving standards. He highlighted the Patient-Centered Outcomes Research Institute (PCORI) as one organization that has really worked hard to include patients.
"PCORI now has patients plugged into every step of the way of their process, which is really a relatively new development and I would say definitely a positive development," Mr Leonard said.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More
